News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,610 Results
Type
Article (14899)
Company Profile (299)
Press Release (266406)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79842)
Career Advice (165)
Deals (13340)
Drug Delivery (39)
Drug Development (50698)
Employer Resources (31)
FDA (5837)
Job Trends (5167)
News (145087)
Policy (10073)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21763)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6031)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (149)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43664)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31648)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51660)
Executive appointments (621)
FDA (7584)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6614)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (19)
IPO (7349)
IRA (12)
Job creations (867)
Job search strategy (131)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2671)
Medtech (2680)
Mergers & acquisitions (6614)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (866)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26649)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15474)
Phase 2 (20285)
Phase 3 (12819)
Pipeline (3239)
Policy (90)
Postmarket research (853)
Preclinical (6536)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1447)
Recruiting (12)
Regulatory (9893)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1205)
Last 365 days (17796)
2026 (1651)
2025 (18098)
2024 (20544)
2023 (22416)
2022 (26827)
2021 (27811)
2020 (23360)
2019 (16228)
2018 (11743)
2017 (13746)
2016 (11840)
2015 (14352)
2014 (10394)
2013 (7488)
2012 (7533)
2011 (7617)
2010 (7430)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18251)
Australia (3110)
California (7074)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39157)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23320)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,610 Results for "clasp therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity
Clasp Therapeutics launched today with $150 million in financing.
March 20, 2024
·
4 min read
Press Releases
Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity
April 28, 2025
·
3 min read
Clasp Emerges with $150M Series A Financing to Advance T Cell Engagers
Clasp Therapeutics announced Wednesday that the Series A funding, which was led in part by Novo Holdings, will support development of its T cell engagers for highly specific tumor targeting.
March 20, 2024
·
2 min read
·
Kate Goodwin
Drug Development
Clasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors
October 4, 2024
·
1 min read
Biotech Bay
CLASP IID One-year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation
Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair therapies, as well as one-year results from the CLASP IID registry.
October 26, 2023
·
5 min read
Press Releases
Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting
November 7, 2024
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Press Releases
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
January 26, 2026
·
4 min read
Press Releases
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
January 28, 2026
·
7 min read
Press Releases
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
January 22, 2026
·
1 min read
1 of 28,161
Next